title: Evaluation of drug resistance in pulmonary tuberculosis patients at Sureyyapasa Chest Diseases Hospital, Istanbul, Turkey.
abstract: METHODS
  Sureyyapasa Chest Diseases and Thoracic Surgery Training Hospital, Istanbul, Turkey.
  
  
  OBJECTIVE
  To determine levels of Mycobacterium tuberculosis resistance to first-line drugs in patients with pulmonary tuberculosis (PTB).
  
  
  METHODS
  Between 1 January and 31 December 2005, all hospitalised PTB patients with culture-positive M. tuberculosis specimens and corresponding drug susceptibility tests (DST) for isoniazid (INH), rifampicin (RMP), streptomycin (SM) and ethambutol, routinely performed for every tuberculosis (TB) case at our centre, were included.
  
  
  RESULTS
  Of a total of 1513 cases, 1277 (84.4%) were new and 236 (15.6%) were previously treated cases. Of the 1513 isolates, 290 (19%) isolates were resistant to at least one of the drugs tested. Resistance among new and previously treated cases was respectively 16.3% (209 of 1277) and 34.3% (81/236). Any SM resistance and any INH resistance were the most common drug resistance in new cases, while any RMP resistance was the most common drug resistance in previously treated cases. Multidrug resistance was detected in 3.2% (n = 41) of new cases and in 13.5% (n = 32) of previously treated cases.
  
  
  CONCLUSIONS
  Planning for TB control requires an assessment of the number and distribution of drug-resistant cases, with laboratories providing accurate and reliable results.
authors.affiliation: Pulmonary Diseases Clinic, Sureyyapasa Chest Diseases and Thoracic Surgery Training Hospital, Istanbul, Turkey.
authors.forename: T
authors.initials: T
authors.lastname: Karagoz
authors.forename: P
authors.initials: P
authors.lastname: Pazarli
authors.forename: O Y
authors.initials: OY
authors.lastname: Mocin
authors.forename: D
authors.initials: D
authors.lastname: Duman
authors.forename: G
authors.initials: G
authors.lastname: Duman
authors.forename: C
authors.initials: C
authors.lastname: Salturk
authors.forename: O
authors.initials: O
authors.lastname: Unal
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012293:Rifampin / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D018088:Tuberculosis, Multidrug-Resistant / Q000453:epidemiology*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000453:epidemiology*; D014421:Turkey / Q000453:epidemiology
chemical_list: D000904:Antibiotics, Antitubercular; D012293:Rifampin